Home › Memory › NCT06647524
Pilot fMRI Studies of Aging-Related Effects of THC
RecruitingPhase 2
Who can join
Ages 18 to 75 · All sexes
Full eligibility criteria
Inclusion Criteria: * CNB use within past 2 years and felt "high" when used. * Able to read, speak, and understand English. * Able and willing to provide written informed consent, and willing to commit to the study protocol. Exclusion Criteria: * Current marijuana tolerance, desire to cut down, or cravings to use during periods of abstinence. * Positive screen for drug or alcohol (except CNB) on test day will result in rescheduling the appointment * History of adverse effects with CNB * CNB users who are abstaining * IQ \<80 on the Wechsler Abbreviated Scale of Intelligence * Inability to comprehend written instructions using the WRAT 4 reading achievement test * Pregnant, breastfeeding, and ineffective birth control methods * Unable or unsafe to have an MRI * Serious medical, neuro-ophthalmological, or neurological illness (e.g. cancer, seizure disorders, encephalopathy * History of head trauma with loss of consciousness \> 30 minutes or concussion lasting 30 days * Focal brain lesion seen on structural MRI * Any medical/neurological condition that could compromise neurocognitive performance (e.g. epilepsy, multiple sclerosis, fetal alcohol syndrome) * Anyone deemed unsafe to study personnel for any reason * Hearing loss such that subject cannot hear sounds at the levels (dB) or pitches (Hz) to be used in the study * Significant pain and/or reduced mobility in the arms
About the study
The purpose of this study is to begin investigating acute impairment of various forms of memory and learning by Tetrahydrocannabinol (THC) in cannabis (CNB) compared to placebo, in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design in young to middle-aged adults.
What is being tested
- THC (drug)
- Placebo (drug)
Sponsor: Yale University · Participants: 10 · Started: Jul 1, 2025
Contact the study team
- Godfrey Pearlson, MD · Phone: 860-305-8921
Official record on ClinicalTrials.gov — NCT06647524
Locations in the U.S.
| Connecticut | Olin Neuropsychiatric Research Center at Hartford Healthcare, Hartford |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.